John Wilding

56.1k total citations · 26 hit papers
450 papers, 35.6k citations indexed

About

John Wilding is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, John Wilding has authored 450 papers receiving a total of 35.6k indexed citations (citations by other indexed papers that have themselves been cited), including 212 papers in Endocrinology, Diabetes and Metabolism, 134 papers in Molecular Biology and 121 papers in Physiology. Recurrent topics in John Wilding's work include Diabetes Treatment and Management (185 papers), Metabolism, Diabetes, and Cancer (114 papers) and Pharmacology and Obesity Treatment (86 papers). John Wilding is often cited by papers focused on Diabetes Treatment and Management (185 papers), Metabolism, Diabetes, and Cancer (114 papers) and Pharmacology and Obesity Treatment (86 papers). John Wilding collaborates with scholars based in United Kingdom, United States and Canada. John Wilding's co-authors include Ofri Mosenzon, Lawrence A. Leiter, Deepak L. Bhatt, Marc S. Sabatine, Darren K. McGuire, Avivit Cahn, Marc P. Bonaca, Thomas A. Zelniker, Eri Kato and Stephen D. Wiviott and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

John Wilding

438 papers receiving 34.6k citations

Hit Papers

Dapagliflozin and Car... 1996 2026 2006 2016 2018 2021 2018 2015 1996 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    2018 4.3k citations Stephen D. Wiviott, Marc P. Bonaca et al. profile →
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.5k citations John Wilding, Melanie J. Davies et al. profile →
  3. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
    2018 1.9k citations Thomas A. Zelniker, Stephen D. Wiviott et al. profile →
  4. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
    2015 1.8k citations John Wilding et al. profile →
  5. A role for glucagon-like peptide-1 in the central regulation of feeding
    1996 1.6k citations John Wilding et al. profile →
  6. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation
    2017 970 citations John Wilding et al. profile →
  7. Management of obesity
    2016 726 citations John Wilding et al. profile →
  8. Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
    2012 694 citations John Wilding et al. The Journal of Clinical Endocrinology & Metabolism profile →
  9. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
    2017 604 citations Mikhail Kosiborod, Matthew A. Cavender et al. Circulation profile →
  10. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
    2018 574 citations Ofri Mosenzon, John Wilding et al. profile →
  11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
    2019 534 citations Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation profile →
  12. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 515 citations John Wilding, Melanie J. Davies et al. Diabetes Obesity and Metabolism profile →
  13. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
    2016 505 citations John Wilding et al. profile →
  14. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
    2013 389 citations John Wilding et al. Diabetes Obesity and Metabolism profile →
  15. Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
    2012 387 citations John Wilding et al. profile →
  16. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
    2021 355 citations Emily Brown, Daniel J. Cuthbertson et al. profile →
  17. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
    2020 313 citations Thomas A. Zelniker, Marc P. Bonaca et al. Circulation profile →
  18. Economic impacts of overweight and obesity: current and future estimates for 161 countries
    2022 281 citations John Wilding et al. profile →
  19. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
    2019 223 citations Marcus Thuresson, Kamlesh Khunti et al. profile →
  20. Economic impacts of overweight and obesity: current and future estimates for eight countries
    2021 213 citations John Wilding et al. profile →
  21. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
    2022 172 citations John Wilding et al. profile →
  22. Tirzepatide for Obesity Treatment and Diabetes Prevention
    2024 133 citations John Wilding et al. profile →
  23. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    2024 123 citations John Wilding et al. profile →
  24. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    2024 102 citations John Wilding et al. profile →
  25. New insights into the treatment of obesity
    2023 83 citations John Wilding et al. Diabetes Obesity and Metabolism profile →
  26. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
    2025 37 citations Melanie J. Davies, John Wilding et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Wilding United Kingdom 80 20.1k 9.5k 8.6k 8.2k 6.6k 450 35.6k
Richard E. Pratley United States 89 16.9k 0.8× 8.8k 0.9× 6.5k 0.8× 10.1k 1.2× 2.9k 0.4× 398 36.0k
Thomas A. Wadden United States 107 11.0k 0.5× 3.7k 0.4× 9.5k 1.1× 16.8k 2.0× 9.9k 1.5× 481 50.6k
James R. Sowers United States 95 14.8k 0.7× 10.0k 1.1× 6.4k 0.8× 8.7k 1.1× 3.2k 0.5× 689 42.7k
Michael D. Jensen United States 85 8.1k 0.4× 5.1k 0.5× 10.5k 1.2× 19.3k 2.4× 3.0k 0.5× 324 37.7k
Matti Uusitupa Finland 90 13.4k 0.7× 6.9k 0.7× 5.3k 0.6× 12.0k 1.5× 2.1k 0.3× 483 37.7k
Markku Laakso Finland 117 23.4k 1.2× 16.3k 1.7× 11.7k 1.4× 13.5k 1.6× 2.9k 0.4× 673 58.2k
Michael Stümvoll Germany 87 7.3k 0.4× 9.8k 1.0× 4.6k 0.5× 11.9k 1.4× 2.2k 0.3× 582 32.0k
Arne Astrup Denmark 112 11.5k 0.6× 7.6k 0.8× 4.9k 0.6× 24.9k 3.0× 7.1k 1.1× 837 51.1k
Leif Groop Sweden 90 14.8k 0.7× 12.4k 1.3× 10.1k 1.2× 7.5k 0.9× 1.4k 0.2× 555 36.8k
Jean‐Pierre Després Canada 82 11.5k 0.6× 3.9k 0.4× 6.5k 0.8× 14.3k 1.7× 2.6k 0.4× 395 39.9k

Countries citing papers authored by John Wilding

Since Specialization
Citations

This map shows the geographic impact of John Wilding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Wilding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Wilding more than expected).

Fields of papers citing papers by John Wilding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Wilding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Wilding. The network helps show where John Wilding may publish in the future.

Co-authorship network of co-authors of John Wilding

This figure shows the co-authorship network connecting the top 25 collaborators of John Wilding. A scholar is included among the top collaborators of John Wilding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Wilding. John Wilding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Jonathan, Andrew S. Williams, Jamie Burgess, et al.. (2024). Efficacy of providing energy expenditure information to guide weight loss interventions in people with obesity: A randomized controlled trial. Clinical Obesity. 15(1). e12703–e12703. 2 indexed citations
2.
3.
Henney, Alex E. & John Wilding. (2023). Obesity: medical management. Medicine. 51(7). 509–514. 2 indexed citations
4.
Patel, Siddharth M., David A. Morrow, Andrea Bellavia, et al.. (2023). Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61. European Journal of Heart Failure. 26(2). 260–269. 4 indexed citations
5.
6.
7.
Furtado, Remo H.M., Itamar Raz, Erica L. Goodrich, et al.. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 145(21). 1581–1591. 19 indexed citations
8.
Moura, Filipe A., Itamar Raz, Avivit Cahn, et al.. (2021). Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis. Circulation. 144(Suppl_1).
9.
Dobbie, Laurence J., Abd A. Tahrani, Uazman Alam, et al.. (2021). Exercise in Obesity—the Role of Technology in Health Services: Can This Approach Work?. Current Obesity Reports. 11(3). 93–106. 18 indexed citations
10.
Oyama, Kazuma, Itamar Raz, Avivit Cahn, et al.. (2021). Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial. European Heart Journal. 43(31). 2958–2967. 49 indexed citations
11.
Zelniker, Thomas A., Marc P. Bonaca, Remo H.M. Furtado, et al.. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 141(15). 1227–1234. 313 indexed citations breakdown →
12.
Zelniker, Thomas A., Stephen D. Wiviott, Itamar Raz, et al.. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 139(17). 2022–2031. 534 indexed citations breakdown →
13.
Furtado, Remo H.M., Marc P. Bonaca, Itamar Raz, et al.. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 139(22). 2516–2527. 235 indexed citations
14.
Zelniker, Thomas A., David A. Morrow, Ofri Mosenzon, et al.. (2019). Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58. Circulation. 2 indexed citations
15.
Kosiborod, Mikhail, Matthew A. Cavender, Alex Z. Fu, et al.. (2017). Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation. 136(3). 249–259. 604 indexed citations breakdown →
16.
Ashrafi, Reza, Paul Modi, Aung Oo, et al.. (2017). Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction. Experimental Physiology. 102(11). 1424–1434. 16 indexed citations
17.
Ashrafi, Reza, Lucy Pickavance, Gershan Davis, et al.. (2016). Altered Left Ventricular Ion Channel Transcriptome in a High-Fat-Fed Rat Model of Obesity: Insight into Obesity-Induced Arrhythmogenesis. Journal of Obesity. 2016. 1–12. 14 indexed citations
18.
Broom, J., et al.. (2002). RANDOMISED TRIAL OF THE EFFECT OF ORLISTAT ON BODY WEIGHT AND CARDIOVASCULAR DISEASE RISK PROFILE IN OBESE PATIENTS: UK MULTIMORBIDITY STUDY. International Journal of Clinical Practice. 56(7). 494–499. 81 indexed citations
19.
English, Patrick, M.A. Ghatei, Irhamadi Malik, Stephen R. Bloom, & John Wilding. (2002). Food Fails to Suppress Ghrelin Levels in Obese Humans. The Journal of Clinical Endocrinology & Metabolism. 87(6). 2984–2984. 407 indexed citations
20.
Wilding, John. (2000). Management of hypertension. BMJ. 320(7234). 576–576. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard E. Pratley Breakdown of academic impact, for papers by Thomas A. Wadden Breakdown of academic impact, for papers by James R. Sowers Breakdown of academic impact, for papers by Michael D. Jensen Breakdown of academic impact, for papers by Matti Uusitupa Breakdown of academic impact, for papers by Markku Laakso Breakdown of academic impact, for papers by Michael Stümvoll Breakdown of academic impact, for papers by Arne Astrup Breakdown of academic impact, for papers by Leif Groop Breakdown of academic impact, for papers by Jean‐Pierre Després
Rankless by CCL
2026